

Item: 7.4

Report to:	NHS Hull Clinical Commissioning Group Board
Date of Meeting:	22 March 2019
Title of Report:	Health Research, Innovation, Evaluation and Improvement Strategy 2019 - 2022
Presented by:	Sarah Smyth, Director of Quality and Clinical Governance/ Executive Nurse & Dr James Crick, Consultant in Public Health Medicine and Associate Medical Director
Authors:	Sarah Smyth, Director of Quality and Clinical Governance/ Executive Nurse, Dr James Crick, Consultant in Public Health Medicine and Associate Medical Director, Dr Joanne Reeve, Hull York Medical School and the Research and Dr Marie Girdham, Research and Development Lead Nurse Manager

STATUS OF THE REPORT:

To approve	<input checked="" type="checkbox"/>	To endorse	<input type="checkbox"/>
To ratify	<input type="checkbox"/>	To discuss	<input type="checkbox"/>
To consider	<input type="checkbox"/>	For information	<input type="checkbox"/>
To note	<input type="checkbox"/>		

PURPOSE OF REPORT:
The Partnership Strategy for Research, Innovation, Evaluation and Improvement has been jointly developed by Hull Clinical Commissioning Group (CCG), Hull City Council (Public Health) and Hull York Medical School (HYMS).

It sets out a vision for supporting research, innovation, evaluation and improvement, as evidence-based interventions can measurably enhance health care and improve the perceptions of the experience of that care by patients, families, and staff in Hull.

Our aims

- We will increase and grow staff awareness, skills and knowledge of using the principles and practice of research, innovation, evaluation, learning and improvement work.
- We will build on the capacity and capability to undertake research, innovation, evaluation and improvement work with a focus on out-of-hospital care, whatever the setting.
- We will increase the involvement by patients and people in Hull in the research cycle from ideas to practice.

RECOMMENDATIONS:

a That the CCG Board approves the Strategy

REPORT EXEMPT FROM PUBLIC DISCLOSURE

No

Yes

If yes, detail grounds for exemption

CCG STRATEGIC OBJECTIVE *(See guidance notes on page 4)*

3, 4, 7, 10 and 11

Short summary as to how the report links to the CCG's strategic objectives

The Hull Partnership Strategy for Research, Innovation, Evaluation and improvement links to the CCG's strategic aims as it will seek to support the work of the Hull Place based plan and outlines a framework for local organisations to work together in a 'place- based' system in order to improve health outcomes for the local population of Hull. The Strategy has been jointly developed by Hull Clinical Commissioning Group, Hull City Council and Hull, York Medical School.

IMPLICATIONS: *(summary of key implications, including risks, associated with the paper),*

Finance	The national mandate for R & D needs to be factored in to the financial planning and budgetary management used towards R & D, for example the National model for Excess treatment costs has financial implications for the CCG.
HR	In meeting the objectives set out in the strategy, there may be potential workforce issues in regard to increasing and growing the skill set of the staff groups concerned.
Quality	The strategy aims to drive forward the quality of health and care outcomes and make an impact to the local population of Hull.
Safety	The legislative frameworks that support R & D link into the Health Research authority (HRA) and set out the safety requirements and assurances needed to minimise any risk to patient safety.

ENGAGEMENT: *(Explain what engagement has taken place e.g. Partners, patients and the public prior to presenting the paper and the outcome of this)*

During the stage(s) of developing the strategy, engagement work has taken place across a range of stakeholders /partners in attaining a shared strategy and the strategy has been developed jointly by Hull CCG, Hull city Council and Hull, York Medical School.

LEGAL ISSUES: *(Summarise key legal issues / legislation relevant to the report)*

As recognised in the Health and Social Care Act (2012) the CCG is mandated to promote research and the use of research evidence.

EQUALITY AND DIVERSITY ISSUES: (summary of impact, if any, of CCG's duty to promote equality and diversity based on Equality Impact Analysis (EIA). **All** reports relating to new services, changes to existing services or CCG strategies / policies **must** have a valid EIA and will not be received by the Committee if this is not appended to the report)

	Tick relevant box
An Equality Impact Analysis/Assessment is not required for this report.	
An Equality Impact Analysis/Assessment has been completed and approved by the lead Director for Equality and Diversity. As a result of performing the analysis/assessment there are no actions arising from the analysis/assessment.	x
An Equality Impact Analysis/Assessment has been completed and there are actions arising from the analysis/assessment and these are included in section xx in the enclosed report.	

THE NHS CONSTITUTION: (How the report supports the NHS Constitution)

This Hull Partnership Strategy for Research, Innovation, Evaluation and Improvement will support the growth and further development for Hull Health to promote and conduct research.